BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

Rhea-AI Summary

BioCardia (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, announced its CEO Peter Altman's participation in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2025. The presentation, scheduled for 3:40 p.m. EDT, will focus on recent business developments and the company's therapeutic pipeline, particularly highlighting their lead product CardiAMP, an autologous cell therapy for treating ischemic heart failure. The session will be moderated by Jim Molloy, AGP's Managing Director of Equity Research Biotechnology & Specialty Pharmaceuticals.

News Market Reaction

-4.08%

1 alert

-4.08% News Effect

On the day this news was published, BCDA declined 4.08%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia^®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.

Dr. Altman will share recent business developments on the Company’s therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure.

Fireside Chat Details:
Date: Wednesday, May 21, 2025
Time: 03:40 p.m. EDT
Speaker: Peter Altman Ph.D., CEO
Moderator: Jim Molloy, AGP Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals
Webcast: https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw

About BioCardia^®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP^® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph^® vascular navigation product platforms. For more information visit www.biocardia.com.

MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120

FAQ

What will BioCardia (BCDA) discuss at the A.G.P. Healthcare Showcase on May 21, 2025?

BioCardia's CEO will discuss recent business developments and the company's therapeutic pipeline, focusing on CardiAMP, their lead autologous cell therapy for ischemic heart failure treatment.

Who is presenting at BioCardia's (BCDA) fireside chat on May 21, 2025?

Peter Altman, Ph.D., BioCardia's CEO, will present at the fireside chat, moderated by Jim Molloy, AGP's Managing Director of Equity Research.

What is BioCardia's (BCDA) main product in development?

BioCardia's lead product is CardiAMP, an autologous cell therapy being developed for the treatment of ischemic heart failure.

What time is BioCardia's (BCDA) presentation at the A.G.P. Healthcare Showcase?

The fireside chat is scheduled for 3:40 p.m. EDT on Wednesday, May 21, 2025.